NCT01044108 - A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

January 5, 2010

Primary Completion Date

December 13, 2010

Study Completion Date

September 20, 2011

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

DRUG

NNC 0070-0002-0453

Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.

DRUG

'2-0453

Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.

DRUG

placebo

Placebo will be administered as a comparator at each dose level.

Trial Locations (1)

47710

Novo Nordisk Investigational Site, Evansville